MA39165A1 - Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires - Google Patents
Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculairesInfo
- Publication number
- MA39165A1 MA39165A1 MA39165A MA39165A MA39165A1 MA 39165 A1 MA39165 A1 MA 39165A1 MA 39165 A MA39165 A MA 39165A MA 39165 A MA39165 A MA 39165A MA 39165 A1 MA39165 A1 MA 39165A1
- Authority
- MA
- Morocco
- Prior art keywords
- crepuscular
- treatment
- benzimidazole
- proline derivatives
- state syndrome
- Prior art date
Links
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- UBSOHWJGTKOSAS-VWMHFEHESA-N 1H-benzimidazole (2S)-pyrrolidine-2-carboxylic acid Chemical class OC(=O)[C@@H]1CCCN1.c1nc2ccccc2[nH]1 UBSOHWJGTKOSAS-VWMHFEHESA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013060630 | 2013-12-04 | ||
| PCT/IB2014/066548 WO2015083094A1 (en) | 2013-12-04 | 2014-12-03 | Use of benzimidazole-proline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39165A1 true MA39165A1 (fr) | 2017-10-31 |
Family
ID=52347368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39165A MA39165A1 (fr) | 2013-12-04 | 2014-12-03 | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9914721B2 (https=) |
| EP (1) | EP3077391B1 (https=) |
| JP (1) | JP6421185B2 (https=) |
| KR (1) | KR102330133B1 (https=) |
| CN (1) | CN105873921B (https=) |
| AU (1) | AU2014358766B2 (https=) |
| CA (1) | CA2930053A1 (https=) |
| CL (1) | CL2016001349A1 (https=) |
| CY (1) | CY1121089T1 (https=) |
| DK (1) | DK3077391T3 (https=) |
| EA (1) | EA029725B1 (https=) |
| ES (1) | ES2696708T3 (https=) |
| HR (1) | HRP20181710T1 (https=) |
| HU (1) | HUE040555T2 (https=) |
| IL (1) | IL245914B (https=) |
| LT (1) | LT3077391T (https=) |
| MA (1) | MA39165A1 (https=) |
| MX (1) | MX366642B (https=) |
| MY (1) | MY179605A (https=) |
| PH (1) | PH12016500985B1 (https=) |
| PL (1) | PL3077391T3 (https=) |
| PT (1) | PT3077391T (https=) |
| SA (1) | SA516371253B1 (https=) |
| SI (1) | SI3077391T1 (https=) |
| TR (1) | TR201815342T4 (https=) |
| UA (1) | UA116053C2 (https=) |
| WO (1) | WO2015083094A1 (https=) |
| ZA (1) | ZA201604502B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| AU2016360245B2 (en) | 2015-11-23 | 2020-07-09 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof |
| LT3619199T (lt) | 2017-05-03 | 2021-09-27 | Idorsia Pharmaceuticals Ltd | 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba |
| EP4138822A1 (en) * | 2020-04-19 | 2023-03-01 | Idorsia Pharmaceuticals Ltd | Medical use of daridorexant |
| ES3059690T3 (en) | 2021-02-02 | 2026-03-23 | Medshine Discovery Inc | Tetrahydropyrrolocyclic compound and application thereof |
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| WO2026012316A1 (zh) * | 2024-07-08 | 2026-01-15 | 石药集团中奇制药技术（石家庄）有限公司 | 苯并咪唑衍生物及其用途 |
| CN120392749A (zh) * | 2025-04-28 | 2025-08-01 | 天津大学 | 一种构造原发性纤毛运动障碍脑积水模型的方法 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| ES2238458T3 (es) | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | Piperidinas para uso como antagonistas de los receptores de orexina. |
| MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| WO2002044172A1 (en) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Morpholine derivatives as antagonists of orexin receptors |
| WO2002090355A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| CZ20033437A3 (cs) | 2001-06-28 | 2004-09-15 | Smithkline Beecham P.L.C. | N-Aroylové cyklické aminové deriváty jako antagonisté orexinového receptoru |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| DE60309481T2 (de) | 2002-09-18 | 2007-06-21 | Glaxo Group Ltd., Greenford | Cyclische n-aroylamine als orexinrezeptorantagonisten |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| PE20050226A1 (es) | 2003-06-04 | 2005-05-18 | Aventis Pharma Sa | Productos aril-heteroaromaticos y composiciones que los contienen |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CA2557163C (en) | 2004-03-01 | 2011-08-16 | Idorsia Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
| AU2007226203A1 (en) | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| JP2010500401A (ja) | 2006-08-15 | 2010-01-07 | アクテリオン ファーマシューティカルズ リミテッド | アゼチジン化合物 |
| JP2010504957A (ja) | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| ES2357992T3 (es) | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| US20100222328A1 (en) | 2007-05-14 | 2010-09-02 | Hamed Aissaoui | 2-cyclopropyl-thiazole derivatives |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2008260647A1 (en) * | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| ES2371514T3 (es) | 2007-07-03 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | Compuestos de 3-aza-biciclo[3.3.0]octano. |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| BRPI0812981A2 (pt) | 2007-07-03 | 2014-12-16 | Glaxo Group Ltd | Derivados de piperidina úteis como antagonistas dos receptores de orexina |
| EP2183246A2 (en) | 2007-07-27 | 2010-05-12 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo-[3.3.0]-octane derivatives |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| JP2010540429A (ja) | 2007-09-24 | 2010-12-24 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類 |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| RU2492167C2 (ru) | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| AU2008340421B2 (en) * | 2007-12-21 | 2013-12-19 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| ES2385699T3 (es) | 2008-02-21 | 2012-07-30 | Actelion Pharmaceuticals Ltd. | Derivados de 2-aza-biciclo-[2,2,1]heptano |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| CA2739344A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| US8710076B2 (en) | 2008-10-21 | 2014-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358713A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
| AU2009324238A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| JP2012522794A (ja) | 2009-04-03 | 2012-09-27 | メルク・シャープ・エンド・ドーム・コーポレイション | レニン阻害薬 |
| EP2421850A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists |
| RU2544862C2 (ru) | 2009-06-09 | 2015-03-20 | Актелион Фармасьютиклз Лтд | Фторированные аминотриазольные производные |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| EP2608787B1 (en) | 2010-08-24 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| EA201370078A1 (ru) | 2010-09-24 | 2013-11-29 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| CA2815179A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| CA2823877C (en) | 2011-02-18 | 2020-01-07 | Idorsia Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| ES2572703T3 (es) | 2011-11-08 | 2016-06-01 | Actelion Pharmaceuticals Ltd. | Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| EA201500399A1 (ru) | 2012-10-10 | 2015-09-30 | Актелион Фармасьютиклз Лтд. | Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона |
| CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
-
2014
- 2014-12-03 SI SI201430931T patent/SI3077391T1/sl unknown
- 2014-12-03 PT PT14827273T patent/PT3077391T/pt unknown
- 2014-12-03 CN CN201480065780.6A patent/CN105873921B/zh active Active
- 2014-12-03 TR TR2018/15342T patent/TR201815342T4/tr unknown
- 2014-12-03 LT LTEP14827273.5T patent/LT3077391T/lt unknown
- 2014-12-03 CA CA2930053A patent/CA2930053A1/en not_active Abandoned
- 2014-12-03 MX MX2016007313A patent/MX366642B/es active IP Right Grant
- 2014-12-03 KR KR1020167017709A patent/KR102330133B1/ko active Active
- 2014-12-03 HU HUE14827273A patent/HUE040555T2/hu unknown
- 2014-12-03 EA EA201600434A patent/EA029725B1/ru not_active IP Right Cessation
- 2014-12-03 MY MYPI2016702036A patent/MY179605A/en unknown
- 2014-12-03 MA MA39165A patent/MA39165A1/fr unknown
- 2014-12-03 US US15/101,871 patent/US9914721B2/en active Active
- 2014-12-03 ES ES14827273T patent/ES2696708T3/es active Active
- 2014-12-03 AU AU2014358766A patent/AU2014358766B2/en active Active
- 2014-12-03 PL PL14827273T patent/PL3077391T3/pl unknown
- 2014-12-03 UA UAA201607117A patent/UA116053C2/uk unknown
- 2014-12-03 EP EP14827273.5A patent/EP3077391B1/en active Active
- 2014-12-03 DK DK14827273.5T patent/DK3077391T3/en active
- 2014-12-03 WO PCT/IB2014/066548 patent/WO2015083094A1/en not_active Ceased
- 2014-12-03 HR HRP20181710TT patent/HRP20181710T1/hr unknown
- 2014-12-03 JP JP2016536607A patent/JP6421185B2/ja active Active
-
2016
- 2016-05-26 PH PH12016500985A patent/PH12016500985B1/en unknown
- 2016-05-30 IL IL245914A patent/IL245914B/en active IP Right Grant
- 2016-06-01 SA SA516371253A patent/SA516371253B1/ar unknown
- 2016-06-02 CL CL2016001349A patent/CL2016001349A1/es unknown
- 2016-07-01 ZA ZA2016/04502A patent/ZA201604502B/en unknown
-
2018
- 2018-11-15 CY CY181101212T patent/CY1121089T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA38333A1 (fr) | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections | |
| MA38287B1 (fr) | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA37831A1 (fr) | Dérivés d'azaindole agissant comme inhibiteur de pi3k | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA33760B1 (fr) | Dérivés spirolactames et leurs utilisations | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA38857B1 (fr) | Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone |